Vismodegib, sold under the brand name Erivedge, is a targeted therapy used to treat basal-cell carcinoma (BCC), the most common type of skin cancer. It is the first Hedgehog signaling pathway inhibitor approved by the U.S. Food and Drug Administration (FDA) for patients with locally advanced or metastatic BCC that cannot be treated with surgery or radiation.
Impurities in vismodegib may develop during synthesis, formulation, storage, or transportation, potentially affecting the efficacy and safety of the drug.
Related Substances
These are structurally related byproducts formed during manufacturing. They must be monitored to ensure compliance with regulatory safety standards.
Degradation Products
Vismodegib is susceptible to degradation due to heat, moisture, or exposure to light, leading to chemical breakdown that can impact its potency. Proper storage is essential to maintain drug stability.
Residual Solvents
Trace solvents used in production must be controlled to meet regulatory guidelines and ensure they remain within safe levels for human use.
Analytical Techniques for Monitoring Impurities
Techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are commonly used to detect and quantify impurities in vismodegib formulations.
Vismodegib may start reducing tumor size within a few weeks, but significant improvement is typically observed within 3 to 6 months of treatment. The response time varies based on the severity of the basal-cell carcinoma.
The most common side effects include muscle spasms, hair loss, weight loss, fatigue, and nausea. Other possible effects include loss of appetite, diarrhea, and taste disturbances.
Clinical studies have shown that vismodegib has a response rate of approximately 30-60% in locally advanced BCC and 10-30% in metastatic BCC, depending on individual patient factors.
Yes, hair loss (alopecia) is a common side effect of vismodegib. It may cause partial or complete loss of scalp, eyebrow, and body hair during treatment, but hair regrowth typically occurs after stopping the medication.
